Brief: Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence
10/07/2025 11:52
July 10 (Reuters) - Pfizer Inc PFE.N: XTANDI® PLUS LEUPROLIDE SIGNIFICANTLY IMPROVES SURVIVAL OUTCOMES IN MEN WITH NON-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH HIGH-RISK BIOCHEMICAL RECURRENCE PFIZER: EMBARK MET KEY SECONDARY ENDPOINT PFIZER INC - XTANDI PLUS LEUPROLIDE IMPROVES OVERALL SURVIVAL PFIZER: NO NEW SAFETY SIGNALS WERE OBSERVED IN ANALYSIS, AND SAFETY RESULTS WERE CONSISTENT WITH DEMONSTRATED SAFETY PROFILE OF XTANDI Source text: ID:nBw5fldBDa Further company coverage: PFE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn